CV Therapeutics Inc (CVTX) to Hold Q4 2007 Earnings Conference Call February 26

CV Therapeutics Inc (NASDAQ:CVTX) will hold a conference call on February 26 at 5:00 pm to discuss the fourth quarter earnings for 2007.

A biopharmaceutical company, CV Therapeutics focuses on the discovery, development and commercialization of new drugs to treat cardiovascular diseases.  The company’s Ranexa was approved in the US by December 31 2006.  Ranexa is used to treat chronic angina for patients who have had no luck being treated with antianginal drugs.  The drug was launched in March 2006.

The company is now developing other drugs, such as regadenoson, as a pharmacologic agent in myocardial perfusion imaging studies.  Regadenoson has completed two Phase III clinical trials.

For more Conference Call related events or to post your own events, visit:

http://events.finditt.com/Events_List.aspx?catid=12